ArticleScience advances2022
SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Displayed and encoded antigens on adenovirus vectors optimize humoral and cellular immune responses in rhesus macaques.Journal of virology · 2026Article
- Yeast-Based Vaccine Platforms: Applications and Key Insights from the COVID-19 Era.Biomolecules · 2026Review
- Moloney Murine Leukemia Virus-like Nanoparticles Pseudo-Typed with SARS-CoV-2 RBD for Vaccination Against COVID-19.International journal of molecular sciences · 2025Article
- Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses.Nature nanotechnology · 2024Article
- Article
- Article
- Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.Virologica Sinica · 2023Article
- Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery.NPJ vaccines · 2023Article
- Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).Human vaccines & immunotherapeutics · 2023Article
- Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.Vaccine · 2023Article
- Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines.bioRxiv : the preprint server for biology · 2023Article
- Biomimetic Nanotechnology for SARS-CoV-2 Treatment.Viruses · 2023Review
- Thermal tolerance role of novel polyamine, caldopentamine, identified in fifth instar Bombyx mori.Amino acids · 2023Article
- Isopeptide BondingViruses · 2023Article
- Article
- Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.Human vaccines & immunotherapeutics · 2022Article
- RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.Translational research : the journal of laboratory and clinical medicine · 2022Article
- RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.mSphere · 2022Article
- SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 10 institutions in 3 countries.
Neil C DalvieDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-7912-0309
Lisa H TostanoskiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-9255-5684
Sergio A Rodriguez-AponteThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-6271-7918
Kawaljit KaurDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.ORCID 0000-0003-2624-9755
Sakshi BajoriaDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.ORCID 0000-0001-8782-0842
Ozan S KumruDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.ORCID 0000-0002-5010-7223
Amanda J MartinotCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-6237-6191
Abishek ChandrashekarCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-7821-5552
Katherine McMahanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-3933-0539
Noe B MercadoCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-7769-7326
Jingyou YuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-0775-6623
Aiquan ChangCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-9482-0979
Victoria M GiffinCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-9783-302X
Felix NampanyaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-4102-1265
Shivani PatelCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-3475-1016
Lesley BowmanSpyBiotech Limited, Oxford Business Park North, Oxford OX4 2JZ, UK.ORCID 0000-0001-6838-7174
Christopher A NaranjoThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Dongsoo YunThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Zach FlinchbaughBioqual, Rockville, MD 20852, USA.
Laurent PessaintBioqual, Rockville, MD 20852, USA.ORCID 0000-0002-2126-3008
Renita BrownBioqual, Rockville, MD 20852, USA.
Jason VelascoBioqual, Rockville, MD 20852, USA.
Elyse TeowBioqual, Rockville, MD 20852, USA.
Anthony CookBioqual, Rockville, MD 20852, USA.
Hanne AndersenBioqual, Rockville, MD 20852, USA.ORCID 0000-0003-1103-9608
Mark G LewisBioqual, Rockville, MD 20852, USA.ORCID 0000-0001-7852-0135
Danielle L CampThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Judith Maxwell SilvermanBill and Melinda Gates Medical Research Institute, Cambridge, MA 02139, USA.ORCID 0000-0001-8299-7155
Gaurav S NagarSerum Institute of India Pvt. Ltd., Pune, India.
Harish D RaoSerum Institute of India Pvt. Ltd., Pune, India.
Rakesh R LotheSerum Institute of India Pvt. Ltd., Pune, India.
Rahul ChandrasekharanSerum Institute of India Pvt. Ltd., Pune, India.
Meghraj P RajurkarSerum Institute of India Pvt. Ltd., Pune, India.
Umesh S ShaligramSerum Institute of India Pvt. Ltd., Pune, India.
Harry KleanthousBill and Melinda Gates Foundation, Seattle, WA 98109, USA.ORCID 0000-0001-7115-235X
Sangeeta B JoshiDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
David B VolkinDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
Sumi BiswasSpyBiotech Limited, Oxford Business Park North, Oxford OX4 2JZ, UK.
J Christopher LoveDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-0921-3144
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-5127-4659
Beth Israel Deaconess Medical Center · USBioqual · USSerum Institute of India (India) · INMassachusetts Institute of Technology · USUniversity of Kansas · USGates Foundation · USRagon Institute of MGH, MIT and Harvard · USScience Oxford · GBTufts University · USUniversity of Oxford · GB
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9MMultidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8MNCI NIH HHS P30 CA014051NIAID NIH HHS T32 AI007387
Abstract
Authorized vaccines against SARS-CoV-2 remain less available in low- and middle-income countries due to insufficient supply, high costs, and storage requirements. Global immunity could still benefit from new vaccines using widely available, safe adjuvants, such as alum and protein subunits, suited to low-cost production in existing manufacturing facilities. Here, a clinical-stage vaccine candidate comprising a SARS-CoV-2 receptor binding domain-hepatitis B surface antigen virus-like particle elicited protective immunity in cynomolgus macaques. Titers of neutralizing antibodies (>10
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.